Diabetes

Casual Glucose Concentrations Predict Post-Surgical Myocardial Injury

Casual Glucose Concentrations Predict Post-Surgical Myocardial Injury

By

Glucose concentration assessment before noncardiac surgery may help clinicians predict the risk for postoperative myocardial injury in patients with and without diabetes.

Single Threshold May Not Be Feasible for Gestational Diabetes

Single Threshold May Not Be Feasible for Gestational Diabetes

Diagnostic thresholds for gestational diabetes should be adapted using local populations.

Nut Intake Reduces HbA1c Among Adults With T2DM

Nut Intake Reduces HbA1c Among Adults With T2DM

A full-nut dose lowered HbA1c and estimated cholesterol levels in LDL particles of a certain diameter.

Independent Relationship Between CV Mortality, Oxidative DNA Damage in Type 2 Diabetes

Independent Relationship Between CV Mortality, Oxidative DNA Damage in Type 2 Diabetes

By

This represents the prospective study confirming an independent relationship between cardiovascular mortality and oxidative DNA damage in type 2 diabetes.

Diabetes Diagnosis May Affect Health Behaviors of Family

Diabetes Diagnosis May Affect Health Behaviors of Family

Small changes in health behaviors were seen in partners of those newly diagnosed with diabetes.

Heart Failure Risk Increased in ALVSD With Diabetes

Heart Failure Risk Increased in ALVSD With Diabetes

Increased risk for heart failure in patients with diabetes and asymptomatic left ventricular systolic dysfunction.

Outcomes of Beta-Blocker Use Elderly With Diabetes After Heart Attack

Outcomes of Beta-Blocker Use Elderly With Diabetes After Heart Attack

By

Investigators examined the outcomes of using various beta-blockers in patients with type 2 diabetes after a myocardial infarction.

Effect of SGLT2 Inhibitors on Heart Failure-Related Hospitalization, Below-Knee Amputation

Effect of SGLT2 Inhibitors on Heart Failure-Related Hospitalization, Below-Knee Amputation

By

Canagliflozin vs other SGLT2 inhibitors and non-SLGT2 inhibitors were examined for the risk for heart failure-related hospitalization and below the knee amputation.

Canagliflozin Trial for T2D With CKD Stopped Early Due to Positive Results

Canagliflozin Trial for T2D With CKD Stopped Early Due to Positive Results

By

A clinical trial assessing canagliflozin (Invokana; Janssen) as an addition to standard-of-care in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) has been stopped early after meeting its pre-specified efficacy criteria.

New Data Support Long-Term Cardiovascular Safety of Linagliptin in T2D

New Data Support Long-Term Cardiovascular Safety of Linagliptin in T2D

By

Results showed the overall safety profile of linagliptin in study patients, including adults with kidney disease, was consistent with previous data.

Preeclampsia, Gestational Hypertension Increases CVD Risk Later in Life

Preeclampsia, Gestational Hypertension Increases CVD Risk Later in Life

By

Women with preeclampsia or gestational hypertension during their first pregnancy were more likely to report increased rates of subsequent chronic hypertension, type 2 diabetes, and hypercholesterolemia compared with women who were normotensive.

CVD Risk Independently Predicted by Poor Lifestyle Factors

CVD Risk Independently Predicted by Poor Lifestyle Factors

By

High BMI, low physical activity levels, and frequent smoking and high genetic risk increased the risk for atrial fibrillation, coronary artery disease, hypertension, stroke, and diabetes.

Cardiovascular Disease Risk Lower in Women With Type 2 Diabetes

Cardiovascular Disease Risk Lower in Women With Type 2 Diabetes

By

Investigators examined gender differences in baseline characteristics and outcomes in patients with t2d and ASCVD.

Effects of Liraglutide on Cardiovascular Events in Hypoglycemia

Effects of Liraglutide on Cardiovascular Events in Hypoglycemia

By

Investigators examined the association between hypoglycemia and cardiovascular outcomes and death.

Calcium Channel Blocker May Benefit Patients With Type 1 Diabetes

Calcium Channel Blocker May Benefit Patients With Type 1 Diabetes

By

For this study, researchers conducted a randomized, double-blind, placebo-controlled Phase 2 trial (N=24) to assess the efficacy and safety of adding oral verapamil for 12 months to a standard insulin regimen in adults with recent-onset type 1 diabetes (age range: 18 to 45 years).

Obesity Paradox Seen in T2DM Modified by Smoking Status

Obesity Paradox Seen in T2DM Modified by Smoking Status

Obesity paradox was pronounced in current smokers and absent in never smokers with type 2 diabetes.

Outcomes of Treatment Strategies in T2D, Stable CAD According to Angina Severity

Outcomes of Treatment Strategies in T2D, Stable CAD According to Angina Severity

Investigators demonstrated that angina severity at baseline should be a less important aspect of the diagnostic and therapeutic algorithm.

Working Longer Hours Tied to Higher Diabetes Risk in Women

Working Longer Hours Tied to Higher Diabetes Risk in Women

Increased risk for diabetes seen in women but not men, and was slightly attenuated after adjustment for mediating factors.

Vascular Mortality Declining in Adults With Diabetes in the United States

Vascular Mortality Declining in Adults With Diabetes in the United States

By

Vascular disease mortality accounted for nearly half of all deaths in type 2 diabetes; now this rate has decreased.

Intensified, Multifactorial Intervention for Type 2 Diabetes Reduces Risk for Heart Failure

Intensified, Multifactorial Intervention for Type 2 Diabetes Reduces Risk for Heart Failure

By

Investigators examined the effect of intensified multifactorial intervention on the risk for heart failure-related hospitalization in patients with type 2 diabetes and microalbuminuria.

Cardiovascular Outcomes in Patients With ACS, Diabetes Using Alirocumab

Cardiovascular Outcomes in Patients With ACS, Diabetes Using Alirocumab

By

Investigators examine the effects of the PCSK9 inhibitor alirocumab in patients with recent acute coronary syndrome and diabetes.

Beta-Blockers Show Varied Effects on Hypoglycemic Mortality Risk in Diabetes

Beta-Blockers Show Varied Effects on Hypoglycemic Mortality Risk in Diabetes

Investigators examined the relationship between the use of β-blockers and incidence of hypoglycemia and risk for mortality in hospitalized patients with diabetes.

Empagliflozin, Liraglutide Reduce Cardiovascular Mortality Risk

Empagliflozin, Liraglutide Reduce Cardiovascular Mortality Risk

By

Investigators conducted a meta-analysis to compare the efficacy of SGLT2i, DPP-4i, and GLP-1 agonists for reducing cardiovascular outcomes.

Type 2 Diabetes Does Not Affect Pneumonia Incidence, Outcomes After Stroke

Type 2 Diabetes Does Not Affect Pneumonia Incidence, Outcomes After Stroke

By

Investigators examined the incidence and outcomes of pneumonia in patients with acute ischemic stroke and type 2 diabetes.

ITCA 650 Shows Efficacy in Reducing Weight, HbA1c in Type 2 Diabetes

ITCA 650 Shows Efficacy in Reducing Weight, HbA1c in Type 2 Diabetes

The ITCA 650, a small titanium osmotic mini-pump, provides a subcutaneous infusion of exenatide over 3 or 6 months.

SGLT2 Inhibitor Use Linked to Lower Risk for Heart Failure, Death in Type 2 Diabetes

SGLT2 Inhibitor Use Linked to Lower Risk for Heart Failure, Death in Type 2 Diabetes

Regardless of presence of preexisting cardiovascular disease, SGLT2 inhibitors were associated with lower risk for death and heart failure.

Fenofibrate Improves Cholesterol Levels in Type 2 Diabetes

Fenofibrate Improves Cholesterol Levels in Type 2 Diabetes

To understand the mechanism underlying the benefit of fenofibrate on vascular complications in patients with type 2 diabetes, investigators assessed carotid intima thickness as a marker of subclinical atherosclerosis.

Plasma Methylglyoxal Levels Associated With CVD, Mortality in Type 2 Diabetes

Plasma Methylglyoxal Levels Associated With CVD, Mortality in Type 2 Diabetes

By

Investigators sought to determine whether methylglyoxal levels are associated with cardiovascular disease in type 2 diabetes.

LV Strain, Hypertrophy Predict Heart Failure in Asymptomatic T2D

LV Strain, Hypertrophy Predict Heart Failure in Asymptomatic T2D

By

Impaired global longitudinal strain and left ventricular hypertrophy may be predictive of incident heart failure in patients with asymptomatic type 2 diabetes.

Clinician Perspective: Examining the Link Between Antipsychotics and Diabetes

Clinician Perspective: Examining the Link Between Antipsychotics and Diabetes

By

Endocrinologist Kevin M. Pantalone, DO, and psychiatrist Christian Kohler, MD, discuss the risk associated with the use of antipsychotic medications in individuals with type 2 diabetes.

Sign Up for Free e-Newsletters